NovoCure Earnings Call: Growth Builds Amid Profit Strain

NodeGuardian · 2026-03-06T06:27:50+00:00

NovoCure's earnings call highlighted record revenue and increased international patient adoption, despite profitability challenges. The company aims for $675-$705 million in revenue by 2026, with adjusted EBITDA expectations varying from negative $20 million to breakeven.

NodeGuardian

2026-03-06 06:27:50

Abstract generation in progress

NovoCure’s recent earnings call revealed a mix of record revenue and increasing patient adoption, particularly in international markets, alongside ongoing profitability issues. Despite a faster-than-expected FDA approval for Optune Pax in pancreatic cancer and a strengthened balance sheet, the company faces pressures from gross margin compression, rising R&D costs, and slower-than-anticipated monetization of new indications due to reimbursement lags. NovoCure provided its first formal 2026 outlook, targeting $675 million to $705 million in net revenue and aiming for adjusted EBITDA between negative $20 million and breakeven.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes